Lilly has been bringing in record revenue from its weight-loss medicines, but continues to diversify its pipeline candidates through acquisitions of biotech companies that are developing new genetic therapies for cancer and other disorders.
The new class of GLP-1 drugs are generally considered safe. Their metabolic effects have been scrutinized in studies, but their psychological impact is far less understood.
The Indianapolis-based pharmaceutical giant and the state’s Office of Energy Development signed a nonbinding letter of intent to explore the potential deployment of small modular reactors.
The Indianapolis-based drugmaker has started shipping the new pill to retail pharmacies.
Trump wrote that he deemed such actions necessary “to address the threatened impairment of the national security posed by imports of pharmaceuticals and pharmaceutical ingredients.”
The daily oral medication, which will be branded as Foundayo, is expected to begin shipping Monday.
Centessa Pharmaceuticals is developing treatments to address daytime sleepiness and other neurological conditions.
The Indianapolis-based drugmaker is challenging a $183.7 million judgment in a case brought by a pharmacist who alleged Lilly made false claims about rebates to the federal Medicaid program.
The companies developing new weight-loss medicines have a problem: People who don’t lose weight quickly figure out they were assigned to take a placebo and are bailing out of their clinical trials.
The late-stage results handily beat earlier trials of the company’s diabetes blockbuster Mounjaro, which racked up sales of $23 billion in 2025.
The Lilly Technology Center investment includes expanding existing capabilities and the establishment of new production lines.
Eli Lilly and Co. has launched a platform that offers employers coverage options for obesity care through a partnership with 18 digital health programs.
Tim Coleman has held positions within information technology at Lilly in research and development, sales and marketing, manufacturing, and human resources.
The Catalyst Scholars Fund is supported by a $69.4 million grant from Lilly Endowment Inc. to the CICP Foundation Inc. and matching commitments from participating universities.
LillyPod, which occupies 30,000 square feet in a room the size of a football field, is capable of crunching massive amounts of data at high speeds and is expected to help the Lilly discover and develop drugs at a faster pace.
While major drugmakers tussle for market supremacy, they are also taking on compound pharmacies that have not stopped selling obesity drugs despite the end of the shortage of such drugs.
Orna is developing a treatment known as CAR-T cell therapy, a form of immunotherapy that trains a person’s own cells to recognize and destroy diseases.
Shares in Indianapolis-based Eli Lilly and Co., a rival to Novo Nordisk in the weight-loss market, also fell after the announcement, dropping 7.8% Thursday.
The president first teased TrumpRx in September while announcing the first of his more than 15 deals with pharmaceutical companies, including Indianapolis-based Eli Lilly and Co., to lower drug prices.
Eli Lilly and Co. shares soared in midday trading Wednesday after the drugmaker reported fourth-quarter results that topped Wall Street expectations.
